Is Novo Nordisk A/S overvalued?

Novo Nordisk A/S (NVO) looks undervalued — trading about 128% below its fair value.

Undervalued

Price

$37.32

Fair value

$85.23

Current P/E

9.3

Normal P/E

21.1

Market cap

$165.72B

Dividend yield

4.7%

Return on equity

59.1%

Sector

Healthcare

Fair value compares NVO's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 3 Oct 2026.

Related stocks